RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Aiming, SCGator, Thanks. Yes it's odd since all the other boards I follow on Yahoo are functioning normally.

I've been trying to keep up to speed on more stocks lately, plus digging into some new ones. The next "big" news for Cortex should be the interim AD results in October. The PET scan portion of the study should be a slam dunk (relatively speaking), since we've already seen clear increases in regional brain glucose utilization in Dr. Deadwyler's primates. The only real question will be how much cognitive improvement a single dose of CX-717 will show in the battery of cognitive psychometric tests they'll also be giving. The high dose is 600 mg, so there's a good chance of seeing at least indications of cognitive improvement after a single dose, which when combined with the PET scan data should give BPs some idea what CX-717 can do. I personally would have preferred seeing the trial designed to have dosing for at least several days or a week.

So it looks like the plot thickens for GTCB. I wasn't that surprised over the additional 4 month delay, since I always considered continued regulatory foot dragging to be the primary risk with the stock (made more serious by the company's lack of cash). At least they did raise some additional money over the summer, which turned out to be a wise move. There's a chance that GTCB could tank under a dollar, as happened earlier this year, followed by a decent rebound. Trying to catch that rebound might be something to consider, although for me that would violate one of my basic trading principles - to never short term trade a stock that you aren't willing to own for the longer term (since if the trade goes badly you're stuck with it). I'm just not willing to own GTCB through the entire regulatory process, so I probably won't try to trade it. After the last big drop under a buck, GTCB came roaring back quickly, but this time the rebound might be considerably less vigorous.